Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Purchases 5,990 Shares of Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 5,990 shares of Burning Rock Biotech stock in a transaction dated Tuesday, June 23rd. The stock was purchased at an average price of $7.50 per share, with a total value of $44,925.00. Following the purchase, the director owned 18,129,186 shares in the company, valued at approximately $135,968,895. This represents a 0.03% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Stock Performance

NASDAQ:BNR opened at $8.96 on Thursday. The business’s fifty day moving average is $12.79 and its 200 day moving average is $20.08. The firm has a market cap of $94.26 million, a price-to-earnings ratio of -10.93 and a beta of 1.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. Burning Rock Biotech Limited Sponsored ADR has a 52-week low of $3.22 and a 52-week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $2.09. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%. The business had revenue of $15.66 million for the quarter, compared to analysts’ expectations of $19.21 million.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Wall Street Zen lowered Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Trading of Burning Rock Biotech

Several large investors have recently modified their holdings of BNR. Marshall Wace LLP bought a new position in shares of Burning Rock Biotech during the fourth quarter valued at approximately $220,000. Prospera Financial Services Inc lifted its stake in Burning Rock Biotech by 26.0% in the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after acquiring an additional 6,430 shares during the period. Renaissance Technologies LLC boosted its holdings in Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after acquiring an additional 4,290 shares in the last quarter. Finally, Crcm LP increased its position in Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares during the period. 30.03% of the stock is owned by institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.